argenx (ARGX) Reports Q1 Loss of EUR1.87

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to argenx (ARGX) Reports Q1 Loss of EUR1.87

argenx reports first quarter 2020 financial results and provides business update

May 14, 2020 1:00 AM EDT

            - Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year -             -  Enrollment paused in ongoing trials under Janssen and LEO Pharma collaborations  -                         - ARGX-117 being evaluated in COVID-19 patients with acute respiratory distress syndrome in collaboration with UZ Gent

            - Management to host conference call today at 3:00 pm CEST (9:00 am ET) -

May 14, 2020 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of... More